Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Linagliptin (Prevaglip vs Trajenta)
NCT02857946Phase 1Completed
- Sponsor
- Genuine Research Center
- Start
- Feb 2016
- Primary completion
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of linagliptin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Genuine Research Center. Primary endpoints: Maximal measured plasma concentration, Area under the concentration-time curve from time zero to the last measurable concentration and 1 more. Started Feb 2016; status: completed.
02
Drugs
linagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02857946.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02857946.